PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

2024-04-02

财报

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Webcast link for interested listeners:

https://edge.media-server.com/mmc/p/2ag2438d

Dial-in registration for sell-side research analysts:

https://register.vevent.com/register/BI45f305acae75480b8cd3b6d5463826de

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

The Company also announced today that members of management will present at the upcoming Bank of America 2024 Health Care Conference in Las Vegas. Management is scheduled to present on Wednesday, May 15 at 9:20 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:

Matt Bacso

VP, Investor Relations and Business Operations

m.bacso@PROCEPT-BioRobotics.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构